Man Group
YMAB

Man Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Man Group’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,004
Closed -$115K – 2440
2025
Q1 		$115K Buy
+26,004
New +$151K ﹤0.01% 2099
2023
Q3 		– Sell
-15,444
Closed -$89.9K – 1824
2023
Q2 		$105K Buy
+15,444
New +$116K ﹤0.01% 1879
2023
Q1 		– Sell
-28,343
Closed -$116K – 1677
2022
Q4 		$138K Buy
28,343
+18,043
+175% +$131K ﹤0.01% 1848
2022
Q3 		$149K Buy
+10,300
New +$171K ﹤0.01% 1814
2018
Q4 		– Sell
-40,000
Closed -$1.06M – 2143
2018
Q3 		$1.06M Buy
+40,000
New +$1.02M ﹤0.01% 1648

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Man Group's YMAB Position: Q2 2025 in Review

Man Group sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 26,004 shares — an estimated $115K sold.

Man Group first reported a position in YMAB in Q3 2018 and held it in 5 quarters. The position peaked at $1.06M in Q3 2018. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • Man Group reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Man Group sold 26,004 Y-mAbs Therapeutics shares in Q2 2025, an estimated $115K.
  • Man Group first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 5 quarters.
  • Man Group's Y-mAbs Therapeutics position peaked at $1.06M in Q3 2018.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on Man Group's 13F filing for Q2 2025, filed 14 Aug 2025.